5-Amino-1MQ 50mg/capsule, 60 caps
5-Amino-1MQ 50mg/capsule, 60 caps
Currently unavailable
NovaMeds
NSI-189 phosphate is a synthetic benzylpiperazine-aminopyridine derivative investigated for its effects on neural progenitor cell biology and hippocampal neurogenesis pathways.
Presentation: NSI-189 Phosphate (20mg/capsule), 60 Capsules.
Illustrative packaging generated with AI.
Not for human or veterinary use.
NSI-189 phosphate is a synthetic benzylpiperazine-aminopyridine derivative investigated for its effects on neural progenitor cell biology and hippocampal neurogenesis pathways.
Unlike compounds that primarily modulate monoamine transporters or neurotransmitter receptors, NSI-189 has been studied for its reported ability to promote proliferation, differentiation, and survival of neural progenitor cells in experimental models.
Research has focused on its effects on hippocampal cell populations, neurogenic signalling pathways, neuronal maturation processes, and structural plasticity mechanisms.
Experimental applications include neural progenitor proliferation assays, neurogenesis pathway investigations, cell differentiation studies, hippocampal tissue modelling, and structure-activity relationship (SAR) research within the benzylpiperazine-aminopyridine compound class.
| Chemical Formula | C22H33N4O5P |
|---|---|
| Synonyms | NSI-189 phosphate 1270138-41-4, UNII-HX0VO60T62, HX0VO60T62, NSI189 Phosphate |
| Molar Mass | 464.5 g/mol |
| CAS Number | 1270138-41-4 |
| PubChem CID | 50922680 |
| Total Compound Content | 1200mg (20mg per capsule) |
| Shelf Life | 36 months |
NSI-189 phosphate is a synthetic benzylpiperazine-aminopyridine derivative investigated for its effects on neural progenitor cell biology and neurogenesis-related pathways. In vitro studies have reported increased neural progenitor cell proliferation and modulation of neuronal differentiation markers following compound exposure. Experimental research commonly utilizes biomarkers such as doublecortin (DCX) and Ki-67 to assess progenitor cell expansion, maturation, and cellular turnover. Unlike compounds that primarily act through monoamine transporters or neurotransmitter receptor systems, NSI-189 is studied for its influence on intracellular signalling pathways associated with progenitor cell growth, differentiation, and structural plasticity. Research applications include neural progenitor proliferation assays, neurogenesis pathway investigation, neuronal differentiation studies, DCX and Ki-67 biomarker analysis, and structure-activity relationship (SAR) research within the benzylpiperazine-aminopyridine compound class. Independently third-party HPLC-tested; COA available per batch.
Results refer to the tested sample. Check the batch and date in the report.
Common experimental approaches include in vitro proliferation assays using neural progenitor cell cultures, with proliferation quantified through markers such as BrdU incorporation or Ki-67 expression. Differentiation studies often monitor changes in neuronal lineage markers, including doublecortin (DCX) and NeuN, over extended culture periods.
Concentration-response experiments are frequently performed to characterize proliferative activity and compare responses across different experimental conditions.
Neurogenesis research typically utilizes immunohistochemical analysis of proliferation markers such as Ki-67 and BrdU, together with immature neuronal markers including doublecortin (DCX). Quantification is commonly performed through stereological cell counting, image-based analysis, and biomarker expression profiling.
Additional assessments may include volumetric imaging and histological measurements to evaluate structural changes associated with prolonged experimental exposure.
NSI-189 phosphate is investigated primarily for its reported effects on progenitor-cell proliferation and neurogenesis-associated signalling pathways rather than direct interaction with monoamine transporters or neurotransmitter receptors.
Mechanistic studies often employ receptor antagonists or pathway-specific inhibitors to determine whether observed cellular effects persist independently of monoaminergic signalling. This approach helps distinguish progenitor-cell-directed activity from secondary effects associated with neurotransmitter-dependent mechanisms.
Capsule excipients are not specified in the available product documentation.